Literature DB >> 10820223

Structure-activity relationships among N-arachidonylethanolamine (Anandamide) head group analogues for the anandamide transporter.

A Jarrahian1, S Manna, W S Edgemond, W B Campbell, C J Hillard.   

Abstract

Two putative endocannabinoids, N-arachidonylethanolamine (AEA) and 2-arachidonylglycerol, are inactivated by removal from the extracellular environment by a process that has the features of protein-mediated facilitated diffusion. We have synthesized and studied 22 N-linked analogues of arachidonylamide for the purpose of increasing our understanding of the structural requirements for the binding of ligands to the AEA transporter. We have also determined the affinities of these analogues for both the CB(1) cannabinoid receptor and fatty acid amide hydrolase (FAAH). We have identified several structural features that enhance binding to the AEA transporter in cerebellar granule cells. We have confirmed the findings of others that replacing the ethanolamine head group with 4-hydroxybenzyl results in a high-affinity ligand for the transporter. However, we find that the same molecule is also a competitive inhibitor of FAAH. Similarly, replacement of the ethanolamine of AEA with 3-pyridinyl also results in a high-affinity inhibitor of both the transporter and FAAH. We conclude that the structural requirements for ligand binding to the CB(1) receptor and binding to the transporter are very different; however, the transporter and FAAH share most, but not all, structural requirements.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10820223     DOI: 10.1046/j.1471-4159.2000.0742597.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  30 in total

Review 1.  The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids.

Authors:  Roger G Pertwee
Journal:  AAPS J       Date:  2005-10-24       Impact factor: 4.009

2.  Pharmacological characterization of endocannabinoid transport and fatty acid amide hydrolase inhibitors.

Authors:  Amy K Dickason-Chesterfield; Stephanie R Kidd; Steven A Moore; John M Schaus; Bin Liu; George G Nomikos; Christian C Felder
Journal:  Cell Mol Neurobiol       Date:  2006-05-31       Impact factor: 5.046

Review 3.  The complications of promiscuity: endocannabinoid action and metabolism.

Authors:  S P H Alexander; D A Kendall
Journal:  Br J Pharmacol       Date:  2007-09-17       Impact factor: 8.739

4.  Antitumorigenic Properties of Omega-3 Endocannabinoid Epoxides.

Authors:  Jahnabi Roy; Josephine E Watson; In Sup Hong; Timothy M Fan; Aditi Das
Journal:  J Med Chem       Date:  2018-06-26       Impact factor: 7.446

Review 5.  Enzymatic pathways that regulate endocannabinoid signaling in the nervous system.

Authors:  Kay Ahn; Michele K McKinney; Benjamin F Cravatt
Journal:  Chem Rev       Date:  2008-04-23       Impact factor: 60.622

6.  Evidence for bidirectional endocannabinoid transport across cell membranes.

Authors:  Andrea Chicca; Janine Marazzi; Simon Nicolussi; Jürg Gertsch
Journal:  J Biol Chem       Date:  2012-08-09       Impact factor: 5.157

7.  Characterization of palmitoylethanolamide transport in mouse Neuro-2a neuroblastoma and rat RBL-2H3 basophilic leukaemia cells: comparison with anandamide.

Authors:  S O Jacobsson; C J Fowler
Journal:  Br J Pharmacol       Date:  2001-04       Impact factor: 8.739

Review 8.  Cellular accumulation of anandamide: consensus and controversy.

Authors:  Cecilia J Hillard; Abbas Jarrahian
Journal:  Br J Pharmacol       Date:  2003-09-01       Impact factor: 8.739

Review 9.  Cannabinoids and multiple sclerosis.

Authors:  Roger G Pertwee
Journal:  Mol Neurobiol       Date:  2007-06-26       Impact factor: 5.590

10.  Anandamide transport is independent of fatty-acid amide hydrolase activity and is blocked by the hydrolysis-resistant inhibitor AM1172.

Authors:  D Fegley; S Kathuria; R Mercier; C Li; A Goutopoulos; A Makriyannis; D Piomelli
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-11       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.